{"id":"https://genegraph.clinicalgenome.org/r/20a0f9b7-b2c5-4473-8bd4-c7f969448ad7v1.1","type":"EvidenceStrengthAssertion","dc:description":"*PLIN1* (previously known as *PERI*; *PLIN*; *FPLD4*) was first reported in relation to autosomal dominant familial partial lipodystrophy (FPLD4, OMIM: 613877) in 2011 (Gandotra et al., PMID: 21345103). The authors described 3 families with familial partial lipodystrophy, insulin resistance, hepatic steatosis, and dyslipidemia that cosegregates with 2 different heterozygous PLIN1 mutations [c.1210-1G > T (p.Leu404Alafs) and c.1191_1192delAG (p.Val398Glyfs)], leading to elongated perilipin 1. Typically, FPLD4 patients are characterized by lipoatrophy predominantly affecting the gluteal region and lower limbs, muscular hypertrophy, most notable on the lower limbs and no lipodystrophy in face and neck. Insulin-resistant diabetes mellitus, polycystic ovary syndrome, acanthosis nigricans, hypertriglyceridemia, hypertension, and hepatic steatosis are also present (Gandorta et al., PMID: 21345103; Kozusko et al., PMID: 25114292; Chen et al., PMID: 29747582). Renal disease has been reported once (Chen et al., PMID: 29747582). At least 5 frame shifting variants that result in the inclusion of aberrant C-terminal amino acids (125-166 amino acids) have been reported in cases of FPLD4, namely c.1191_1192del (p.Val398Glyfs; PMIDs: 21345103, 31504636), c.1201_1202dup (p.Val402Thrfs, PMID: 29747582), c.1202_1205dup (p.Pro403Argfs; PMID: 31504636), c.1308_1309del (p.Pro439Valfs; PMID: 25114292) and c.1210-1G-T (p.Leu404Alafs; PMID: 21345103) in at least 10 probands  in different publications (PMIDs: 21345103; 25114292; 29747582; 31504636). Of note, histological examination of subcutaneous adipose tissue from patients revealed a significant decrease in adipocyte size, macrophage infiltration, and increased fibrosis (PMID: 21345103). For the purpose of this curation, all 10 probands are included. *Heterozygous null variants predicted to undergo nonsense-mediated decay (NMD) are relatively frequent in the population and clinical datasets and are not associated with FPLD4, thus indicating that haploinsufficiency is not a disease mechanism PLIN1-related lipodystrophy (Laver et al., PMID: 30020498, Koprulu et al. PMID: 34875679, Patel et al., PMID: 35235652); rather, it is associated with a favorable lipid profile. *Instead, the disorder results specifically from dominant-negative effects of C-terminal elongating frameshift variants predicted to escape NMD. Mechanistic studies suggest that subcutaneous patients’ adipose tissues show reduced full-length perilipin-1 and an extended perilipin-1 form compatible with the predicted elongated C-terminal tail of the mutant proteins (PMIDs: 21345103; 25114292; 31504636). Patients’ adipose tissues are also characterized by smaller adipocytes, increased macrophage infiltration and fibrosis (PMIDs: 21345103; 31504636). All but one (i.e. (p.Pro439Valfs; PMID:25114292) FPLD4-associated *PLIN1* variants [p.(Val398Glyfs), p.(Pro403Argfs), p.(Leu404Alafs)] alter the interaction domain of perilipin-1 with ABHD5 (PMIDs: 21757733; 31504636). Consistently, the p.(Val398Glyfs) and p.(Leu404Alafs) mutants fail to interact with ABHD5, leading to constitutive activation of adipocyte triglyceride lipase (PMIDs: 21345103). Although the p.(Pro439Valfs) mutant binds ABHD5, it fails to inhibit basal lipolysis probably by an alternate still unknown mechanism (PMID:25114292). *Plin1* homozygous knockout mice display a significant reduction in adipose tissue mass, approximately 30% of that observed in wild-type counterpart. Their Isolated adipocytes show elevated basal lipolysis because of the loss of the protective function of perilipin. In addition, these adipocytes show markedly reduced stimulated lipolytic activity, thus suggesting that perilipin is essential for maximal lipolysis. *Plin1* homozygous knockout mice also exhibit greater lean body mass, elevated metabolic rates, and are more prone to glucose intolerance and peripheral insulin resistance (Tansey et al., PMID: 11371650). Furthermore, adipogenic signaling is disrupted in these mice, resulting in abnormal lipid droplet growth and differentiation (Lyu et al., PMID:25695774, Patel et al., PMID: 35235652). Heterozygous knockout mice have a non-significantly lower fat mass.  Experimental evidence: 6 points. Total evidence:  18 points. In summary, there is definitive evidence supporting the relationship between *PLIN1* and autosomal dominant familial partial lipodystrophy (FPLD4, OMIM: 613877).  *Only frameshift variants extending the C-terminus have to date been implicated in humans.  Homozgyous null variants have not been observed in humans, and heterozgyous null variants are not associated with lipodystrophy in humans.  *\nThis classification was approved by the ClinGen Monogenic Diabetes GCEP on September 10, 2025 (Gene-Disease Clinical Validity Standard Operating Procedures (SOP) - SOP11).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/20a0f9b7-b2c5-4473-8bd4-c7f969448ad7","GCISnapshot":"https://genegraph.clinicalgenome.org/r/dcba327c-dc89-4e78-ae7b-84b23db5429e","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:classificationChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/dcba327c-dc89-4e78-ae7b-84b23db5429e_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2025-09-10T16:42:23.955Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/dcba327c-dc89-4e78-ae7b-84b23db5429e_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2025-09-10T16:00:00.000Z","role":"Approver"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dcba327c-dc89-4e78-ae7b-84b23db5429e_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3441b1e5-2f23-4001-a21f-440393312d01","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3441b1e5-2f23-4001-a21f-440393312d01_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29747582","allele":{"id":"https://genegraph.clinicalgenome.org/r/5aebad11-4166-4ecd-a0fb-7351b38e832c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002666.5(PLIN1):c.1201_1202dup (p.Val402ThrfsTer9)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573054118"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/5e2a8f6d-95da-4b69-b87a-e5a996fa5a52","type":"EvidenceLine","dc:description":"Fuctional data support score upgrading of this variant.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e2a8f6d-95da-4b69-b87a-e5a996fa5a52_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","allele":{"id":"https://genegraph.clinicalgenome.org/r/f691a2d4-16bd-4e87-b3e5-b7b2b4872337","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002666.5(PLIN1):c.1202_1205dup (p.Pro403ArgfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695221098"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/5e2a8f6d-95da-4b69-b87a-e5a996fa5a52_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Thr 4bp-duplication in exon 8 (c.1202_1205dup), leads to the synthesis of a p.(Pro403Argfs*164) mutant protein whose expression in adipose tissue from different patients (i.e. E-I1 and E-II-2 ) was confirmed by Western blot (Fig. 2 A). In addition, histological and immunohistological analyses of abdominal subcutaneous adipose tissue from patients E-I1 and E-II-2 displayed disorganized fat lobules of heterogeneous size and increased fibrosis, vascularization macrophage infiltration as compared to controls (Fig. 2 C).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/31352382-1f6b-4647-8e57-d2e5ec977965","type":"EvidenceLine","dc:description":"Fuctional data support score upgrading of this variant.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31352382-1f6b-4647-8e57-d2e5ec977965_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25114292","allele":{"id":"https://genegraph.clinicalgenome.org/r/479dc59e-f5e9-4611-8781-1084c200876e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002666.5(PLIN1):c.1308_1309del (p.Pro439ValfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573054117"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/31352382-1f6b-4647-8e57-d2e5ec977965_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional studies showed that expression levels of the mutant 439fs protein were lower than wild-type perilipin, despite equivalent mRNA expression levels.\nIn stably transfected preadipocytes, the mutant protein was associated with smaller lipid droplets compared to cells expressing wild-type perilipin.\n439fs variant stabilize ABHD5 expression, but it failed to inhibit basal lipolysis as effectively as wild-type perilipin-1.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/dcba327c-dc89-4e78-ae7b-84b23db5429e_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b71f6d3b-c008-4e9e-8db5-ffb19358ece6_proband_segregation","type":"FamilyCosegregation","dc:description":"Autosomal dominant conditions with only 2  segregations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345103","rdfs:label":"Gandotra_Case2","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/b71f6d3b-c008-4e9e-8db5-ffb19358ece6","type":"Family","rdfs:label":"Gandotra_Case2","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/85f0e29f-dfec-4631-a9f5-22ab3711ad5a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345103","rdfs:label":"Gandrota_Case2 _Patient2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":50,"allele":{"id":"https://genegraph.clinicalgenome.org/r/d14b7012-014b-41a2-9a16-27e6a2c5b0ce","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002666.5(PLIN1):c.1191_1192del (p.Val398GlyfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA891844096"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0002155","obo:HP_0008981","obo:HP_0100578","obo:HP_0030685","obo:HP_0003635","obo:HP_0000822","obo:HP_0000956","obo:HP_0001397","obo:HP_0003292"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/1ce57363-4069-4060-a553-1bfe18c15ace_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345103","allele":{"id":"https://genegraph.clinicalgenome.org/r/d14b7012-014b-41a2-9a16-27e6a2c5b0ce"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0009017","obo:HP_0002155","obo:HP_0030685","obo:HP_0100578","obo:HP_0003292","obo:HP_0008981","obo:HP_0003635","obo:HP_0000822","obo:HP_0000819","obo:HP_0000956","obo:HP_0001397"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/85f0e29f-dfec-4631-a9f5-22ab3711ad5a"}},{"id":"https://genegraph.clinicalgenome.org/r/7dabbc97-bd79-4b94-b667-c53b1e479d15_proband_segregation","type":"FamilyCosegregation","dc:description":"Autosomal dominant condition with only 2 segregations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","rdfs:label":"Jerù_Family C","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/7dabbc97-bd79-4b94-b667-c53b1e479d15","type":"Family","rdfs:label":"Jerù_Family C","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/1d3e48b2-f5da-4309-95cd-5062218d79ff","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","rdfs:label":"Jerù_FamilyC_proband C-II1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f691a2d4-16bd-4e87-b3e5-b7b2b4872337"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0001397","obo:HP_0003712","obo:HP_0000842","obo:HP_0000876","obo:HP_0003635","obo:HP_0000956","obo:HP_0009017","obo:HP_0100578","obo:HP_0000819","obo:HP_0000280","obo:HP_0002155"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5e2a8f6d-95da-4b69-b87a-e5a996fa5a52_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0002155","obo:HP_0009017","obo:HP_0000876","obo:HP_0000280","obo:HP_0000956","obo:HP_0000147","obo:HP_0001397","obo:HP_0000842","obo:HP_0003712","obo:HP_0003635","obo:HP_0100578","obo:HP_0000819"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/1d3e48b2-f5da-4309-95cd-5062218d79ff"}},{"id":"https://genegraph.clinicalgenome.org/r/7a6467d1-9af3-494e-8b93-da74584f72c4_proband_segregation","type":"FamilyCosegregation","dc:description":" Autosomal dominant conditions with 3 segragations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25114292","rdfs:label":"Kozusko_Kindred A","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/7a6467d1-9af3-494e-8b93-da74584f72c4","type":"Family","rdfs:label":"Kozusko_Kindred A","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/c279f9b6-5c21-430e-b5d3-4b25578a6a62","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25114292","rdfs:label":"Kozusko_Kindred A_I.1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":42,"allele":{"id":"https://genegraph.clinicalgenome.org/r/479dc59e-f5e9-4611-8781-1084c200876e"},"detectionMethod":"Coding regions and splice junctions of PLIN1 were amplified by PCR and sequenced by Sanger sequencing","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0100578","obo:HP_0000822","obo:HP_0000956","obo:HP_0002155"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/943b63e7-d7db-433d-ad5f-92ca3ad39c67_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25114292","allele":{"id":"https://genegraph.clinicalgenome.org/r/479dc59e-f5e9-4611-8781-1084c200876e"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"phenotypePositiveAllelePositive":4,"proband":{"id":"https://genegraph.clinicalgenome.org/r/c279f9b6-5c21-430e-b5d3-4b25578a6a62"}},{"id":"https://genegraph.clinicalgenome.org/r/6d172f33-0391-4733-94d2-cb2c654a445c_proband_segregation","type":"FamilyCosegregation","dc:description":"Autosomal dominant conditions, including oly 1 segregation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29747582","rdfs:label":"Chen_Family","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/6d172f33-0391-4733-94d2-cb2c654a445c","type":"Family","rdfs:label":"Chen_Family","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/a8690109-b99c-42c8-a493-fdd8680a44cd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29747582","rdfs:label":"Chen_Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5aebad11-4166-4ecd-a0fb-7351b38e832c"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0008981","obo:HP_0000855","obo:HP_0002155","obo:HP_0100578","obo:HP_0001397","obo:HP_0000147","obo:HP_0000956","obo:HP_0000096"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3441b1e5-2f23-4001-a21f-440393312d01_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0100578","obo:HP_0008981","obo:HP_0000147","obo:HP_0000956","obo:HP_0000855","obo:HP_0002155","obo:HP_0001397"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/a8690109-b99c-42c8-a493-fdd8680a44cd"}},{"id":"https://genegraph.clinicalgenome.org/r/6f4aeddb-b5af-49f0-adf6-57f95bdf6ab1_proband_segregation","type":"FamilyCosegregation","dc:description":"Autosomal dominant condition with 2 segregations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","rdfs:label":"Jerù_Family E","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/6f4aeddb-b5af-49f0-adf6-57f95bdf6ab1","type":"Family","rdfs:label":"Jerù_Family E","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/33164af7-eb8c-4ac8-8734-244c8835171a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","rdfs:label":"Jerù_FamilyE_Patient E-II2","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":38,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f691a2d4-16bd-4e87-b3e5-b7b2b4872337"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0003712","obo:HP_0002155","obo:HP_0000280","obo:HP_0100578","obo:HP_0000819"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/16ef65d9-472e-4e86-a4cc-59adbbf86db3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","allele":{"id":"https://genegraph.clinicalgenome.org/r/f691a2d4-16bd-4e87-b3e5-b7b2b4872337"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0003712","obo:HP_0100578","obo:HP_0000280","obo:HP_0000819","obo:HP_0002155"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/33164af7-eb8c-4ac8-8734-244c8835171a"}},{"id":"https://genegraph.clinicalgenome.org/r/34d79145-008c-4912-a7cf-c7626af152b4_proband_segregation","type":"FamilyCosegregation","dc:description":"Autosomal dominant conditions with only 1 segregations. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25114292","rdfs:label":"Kozusko_Kindred B","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/34d79145-008c-4912-a7cf-c7626af152b4","type":"Family","rdfs:label":"Kozusko_Kindred B","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/06bcfce1-f809-4102-a30c-fad20628ad73","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25114292","rdfs:label":"Kozusko_Kindred B Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/479dc59e-f5e9-4611-8781-1084c200876e"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0000956","obo:HP_0000855","obo:HP_0001397","obo:HP_0002155","obo:HP_0003635","obo:HP_0002240"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/31352382-1f6b-4647-8e57-d2e5ec977965_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0003635","obo:HP_0002240","obo:HP_0000855","obo:HP_0000956","obo:HP_0001397","obo:HP_0002155"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/06bcfce1-f809-4102-a30c-fad20628ad73"}},{"id":"https://genegraph.clinicalgenome.org/r/71a3aa33-8d7f-4cda-a809-85052ffcb096_proband_segregation","type":"FamilyCosegregation","dc:description":"Autosomal dominant condition with only 1 segregation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","rdfs:label":"Jerù_Family D","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/71a3aa33-8d7f-4cda-a809-85052ffcb096","type":"Family","rdfs:label":"Jerù_Family D","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/2f0508ea-6764-405c-ad71-09c1e1a981e8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","rdfs:label":"Jerù_FamilyD_Patient D-II3","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/d14b7012-014b-41a2-9a16-27e6a2c5b0ce"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0000147","obo:HP_0100578","obo:HP_0003712","obo:HP_0000280","obo:HP_0001397","obo:HP_0000855","obo:HP_0002155","obo:HP_0000956"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/e2552306-d3ec-43a8-90f8-25c3964a05e6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","allele":{"id":"https://genegraph.clinicalgenome.org/r/d14b7012-014b-41a2-9a16-27e6a2c5b0ce"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0000956","obo:HP_0001397","obo:HP_0002155","obo:HP_0000855","obo:HP_0000280","obo:HP_0003712","obo:HP_0000147","obo:HP_0100578","obo:HP_0000819"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/2f0508ea-6764-405c-ad71-09c1e1a981e8"}},{"id":"https://genegraph.clinicalgenome.org/r/636868ff-d9e7-4579-adb9-43355f692079_proband_segregation","type":"FamilyCosegregation","dc:description":"This family has less than 4 segregations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345103","rdfs:label":"Gandotra_Case1","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/636868ff-d9e7-4579-adb9-43355f692079","type":"Family","rdfs:label":"Gandotra_Case1","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/902187f7-3d3b-4d3a-b4b2-10e2f50de399","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345103","rdfs:label":"Gandrota_Case1 Patient1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":54,"allele":{"id":"https://genegraph.clinicalgenome.org/r/463edc38-c9ba-4595-bdb7-86115c8b6e0b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002666.5(PLIN1):c.1210-1G>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA393789983"}},"detectionMethod":"The entire coding region and splice junctions of PLIN1 (GenBank accession number, NM_002666.4) were amplified and sequenced.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b7d32d2a-39ac-418b-9c1f-b6e4b9aca364_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345103","allele":{"id":"https://genegraph.clinicalgenome.org/r/463edc38-c9ba-4595-bdb7-86115c8b6e0b"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0030685","obo:HP_0000822","obo:HP_0008981","obo:HP_0000842","obo:HP_0000956","obo:HP_0002155","obo:HP_0001397","obo:HP_0003292","obo:HP_0009017","obo:HP_0000819","obo:HP_0003635","obo:HP_0100578"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/902187f7-3d3b-4d3a-b4b2-10e2f50de399"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1ce57363-4069-4060-a553-1bfe18c15ace","type":"EvidenceLine","dc:description":"Fuctional data support score upgrading of this variant.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1ce57363-4069-4060-a553-1bfe18c15ace_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/1ce57363-4069-4060-a553-1bfe18c15ace_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Subcutaneous fat from patients with this variant showed reduced full-length perilipin and a predicted elongated C-terminal tail of the mutant proteins, as indicated by Western blot analyses. The same tissue was characterized by smaller-than-normal adipocytes, macrophage infiltration, and fibrosis. Moreover, mutant protein forms failed to increase triglyceride accumulation when heterologously expressed in preadipocytes.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/81dd30f9-8843-473b-b2ca-f2b206d84b5e","type":"EvidenceLine","dc:description":"Fuctional data support score upgrading of this variant.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/81dd30f9-8843-473b-b2ca-f2b206d84b5e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","allele":{"id":"https://genegraph.clinicalgenome.org/r/d14b7012-014b-41a2-9a16-27e6a2c5b0ce"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/81dd30f9-8843-473b-b2ca-f2b206d84b5e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The p.Val398fs fails to suppress ABHD5–ATGL interaction, leading to increased basal lipolysis. This provides evidence for a “dominant-negative/protein misregulation” mechanism consistent with the clinical phenotype. The 439fs variant shows defects in the regulation of lipolysis in cellular models. Also, adipose tissue biopsies from patients carrying this mutation reveal small adipocytes, accompanied by inflammation and fibrosis (PMIDs:21345103, 21757733, 25114292).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b7d32d2a-39ac-418b-9c1f-b6e4b9aca364","type":"EvidenceLine","dc:description":"Functional data support the upgrading of this variant","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b7d32d2a-39ac-418b-9c1f-b6e4b9aca364_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/b7d32d2a-39ac-418b-9c1f-b6e4b9aca364_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Subcutaneous fat from patients with this variant showed reduced full-length perilipin and a predicted elongated C-terminal tail of the mutant proteins, as indicated by Western blot analyses. The same tissue was characterized by smaller-than-normal adipocytes, macrophage infiltration, and fibrosis.\nMoreover, mutant protein forms failed to increase triglyceride accumulation when heterologously expressed in preadipocytes","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/943b63e7-d7db-433d-ad5f-92ca3ad39c67","type":"EvidenceLine","dc:description":"Fuctional data support score upgrading of this variant.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/943b63e7-d7db-433d-ad5f-92ca3ad39c67_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/943b63e7-d7db-433d-ad5f-92ca3ad39c67_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional studies showed that expression levels of the mutant 439fs protein were lower than wild-type perilipin, despite equivalent mRNA expression levels.\nIn stably transfected preadipocytes, the mutant protein was associated with smaller lipid droplets compared to cells expressing wild-type perilipin.\n439fs variant stabilize ABHD5 expression, but it failed to inhibit basal lipolysis as effectively as wild-type perilipin-1.\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/bd57d07e-1c7d-47be-837c-d33f4f79a1b1","type":"EvidenceLine","dc:description":"Fuctional data support score upgrading of this variant.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bd57d07e-1c7d-47be-837c-d33f4f79a1b1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345103","allele":{"id":"https://genegraph.clinicalgenome.org/r/d14b7012-014b-41a2-9a16-27e6a2c5b0ce"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/bd57d07e-1c7d-47be-837c-d33f4f79a1b1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Subcutaneous fat from patients with this variant showed reduced full-length perilipin and a predicted elongated C-terminal tail of the mutant proteins, as indicated by Western blot analyses. The same tissue was characterized by smaller-than-normal adipocytes, macrophage infiltration, and fibrosis. Moreover, mutant protein forms failed to increase triglyceride accumulation when heterologously expressed in preadipocytes.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/16ef65d9-472e-4e86-a4cc-59adbbf86db3","type":"EvidenceLine","dc:description":"Fuctional data support score upgrading of this variant.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/16ef65d9-472e-4e86-a4cc-59adbbf86db3_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/16ef65d9-472e-4e86-a4cc-59adbbf86db3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":" Thr 4bp-duplication in exon 8 (c.1202_1205dup), leads to the synthesis of a p.(Pro403Argfs*164) mutant protein whose expression in adipose tissue was confirmed by Western blot (Fig. 2). In addition,  histological and immunohistological analyses of abdominal subcutaneous adipose tissue from patients E-I1 and E-II-2 displayed disorganized fat lobules of heterogeneous size and increased fibrosis, vascularization macrophage infiltration as compared to controls.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e2552306-d3ec-43a8-90f8-25c3964a05e6","type":"EvidenceLine","dc:description":"Fuctional data support score upgrading of this variant.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2552306-d3ec-43a8-90f8-25c3964a05e6_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/e2552306-d3ec-43a8-90f8-25c3964a05e6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The p.Val398fs fails to suppress ABHD5–ATGL interaction, leading to increased basal lipolysis. This provides evidence for a “dominant-negative/protein misregulation” mechanism consistent with the clinical phenotype. The 439fs variant shows defects in the regulation of lipolysis in cellular models. Also, adipose tissue biopsies from patients carrying this mutation reveal small adipocytes, accompanied by inflammation and fibrosis (PMIDs:21345103, 21757733, 25114292).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/dcba327c-dc89-4e78-ae7b-84b23db5429e_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dcba327c-dc89-4e78-ae7b-84b23db5429e_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/afe92f3a-bc18-4ab1-9023-8b36aa37bd6c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/05423854-80fc-405d-aeca-0d4371e0120a","type":"Finding","dc:description":"Subcutaneous fat from patients with this variant showed reduced full-length perilipin and a predicted elongated C-terminal tail of the mutant proteins, as indicated by Western blot analyses (figure 2A).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","rdfs:label":"Western blot in subcutaneous adipose tissue from Family E","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/16f785ff-8306-4350-96e9-68d5c52a7b04","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/90e71b9c-2cba-4d06-a633-6c5eff9acc1a","type":"Finding","dc:description":"Both the WT and 439fs copy of perilipin 1 are detectable with an N-terminal epitope-targeted antibody; however, the higher molecular weight band corresponding to the 439fs protein was not detected by an antibody that targets a COOH-terminal epitope. Notably, the levels of WT and particularly the 439fs protein were reduced in the patient compared with control subjects.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25114292","rdfs:label":"Western blot in probands subcutaneous adipose tissue","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1e3eb0d1-44d8-4c30-922c-f4b83afc6b6a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0c683c8e-c65b-42a7-ba21-8c8089528742","type":"Finding","dc:description":" The C-terminal frame shift mutants of PLIN1 (i.e. p.Leu-404fs and p.Val-398fs ) failed to increase ABHD5 protein levels and showed significantly reduced binding to ABHD5 compared to wild-type PLIN1.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21757733","rdfs:label":"ABHD5 Binding by Bimolecular Fluor complementation","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6ab7fa64-bcd3-4b67-89f9-facfafd61b18","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/85b878fe-a710-43bf-a729-5433b32dcf54","type":"Finding","dc:description":"The increased basal lipolysis observed with these mutations is consistent with the phenotype of patients who carry these novel C-terminal PLIN1 frame shift mutations, which include partial lipodystrophy, hypertriglyceridemia, severe insulin resistance, and type 2 diabetes.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21757733","rdfs:label":"Impaired Inhibition of Basal Lipolysis by PLIN1 mutant ","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/dcba327c-dc89-4e78-ae7b-84b23db5429e_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9325ecc9-674c-437c-ad93-0fcf937fa48f","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/041037ac-1406-479a-b4d3-55dc940acf4a","type":"FunctionalAlteration","dc:description":"Subdominal subcutaneous adipose tissue, studied in patients E-I1 and E-II2, displayed disorganized fat lobules of heterogeneous size, with macrophage infiltrates, increased fibrosis, and increased vascularization (Figure 2 C).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31504636","rdfs:label":"Effects of the PLIN1 Variants on Adipose Tissue"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/778bb98d-477c-43d5-8aa6-e8ef0c548e6d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/35a6d8f3-937f-497f-8577-d66ef768416d","type":"FunctionalAlteration","dc:description":"The 439fs variant was found to bind and stabilize ABHD5 expression. However, it still failed to inhibit basal lipolysis as effectively as wild-type perilipin 1. Indeed, in stably transfected 3T3-L1 preadipocytes , WT perilipin 1 significantly suppressed FFA release, whereas the 439fs perilipin 1 mutant did so less effectively.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25114292","rdfs:label":"Basal lipolysis measuraments"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/dfe2696e-54f4-4be8-9cd4-5ee442b697ea","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/badbc32d-ff62-47e3-8b63-f40fbb26436b","type":"FunctionalAlteration","dc:description":"Experiments in 3T3L1 transfected cells show that expression of wild-type perilipin significantly inhibited basal lipolysis in preadipocytes (by more than 50%), as compared with cells transfected with the empty vector (P<0.001), whereas basal lipolysis was unaltered in cells expressing the perilipin mutants (i.e. p.Val398fs/p.Leu404fs), as indicated by 14C-labeled oleic acid release into culture medium.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345103","rdfs:label":"Basal lipolysis"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7853e847-3bfb-4c2a-8faf-c060ce2b1952","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/990fbb04-997e-4245-8435-dbbc23c4f17b","type":"FunctionalAlteration","dc:description":"Isolated adipocytes from peri-/- mice showed elevated basal lipolysis due to the absence of perilipin's protective function, but dramatically attenuated stimulated lipolytic activity. This indicates perilipin is crucial for maximal lipolytic activity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11371650","rdfs:label":"Basal lipolysis"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4f05a518-ae42-45f8-9537-41abd08ec3fc","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/321303ec-f118-491b-9b71-6de45dcb3863","type":"FunctionalAlteration","dc:description":"Fig. 1D shows immunoblots show perilipin expression in samples of white adipose tissue from patients affected Extracellular-signal-regulated kinase (ERK) 1/2 was used as a gel-loading control. Samples of abdominal subcutaneous adipose tissue from three healthy, lean, nondiabetic women were used as controls. Immunoblotting was done with N-terminal and C-terminal perilipin antibodies. The mutant isoform was recognized by the N-terminal antibody as a frameshifted band (arrow) just above the 62-kD molecular-weight (MW) marker. This extra band was not detected by the C-terminal antibody.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345103","rdfs:label":"Western blot analyses"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/89738d16-3e87-4a4d-b572-abe44aeba353","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bd02b103-efa8-4d47-8644-8cc31b9f6368","type":"FunctionalAlteration","dc:description":"In PLIN1-related FPL patients (n=6 for kinetic study; n=5 for adipose tissue analyses), a marked reduction of fractional catabolic rates of VLDL-apoB100 and IDL-apoB100 was observed compared with healthy controls. VLDL-apoB100 production was not increased. Plasma LPL mass was significantly decreased (21.03 ± 10.08 vs 55.76 ± 13.10 ng/mL; p<0.0001), whereas adipose tissue LPL protein expression was similar to controls. Catabolic rates correlated negatively with plasma triglycerides and positively with plasma LPL mass. This reduction is suggested to be a major factor contributing to the hypertriglyceridemia.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38899472","rdfs:label":"In vivo lipoprotein kinetic study"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9ce12a87-a12e-4948-8834-ba481c3020c9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ff335fe4-cc8b-45ba-966d-a669e70e115f","type":"FunctionalAlteration","dc:description":"When overexpressed in 3T3L1 preadipocytes, PLIN1 mutants fail to bind ABHD5 (as indicated by bimolecular fluorescence complementation assays), allowing its constitutive coactivation of ATGL, thus resulting in increased basal lipolysis.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21757733","rdfs:label":"Bimolecular Fluorescence Complementation in transfected cell"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9b73cb8a-7ecf-4c69-992a-0bbd2eb5e41d","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/44489998-478b-48e1-ad9a-2a7c76026cc8","type":"FunctionalAlteration","dc:description":"Subcutaneous fat from patients was characterized by by smaller adipocytes,  increased macrophage infiltration and fibrosis as compared to that of controls  ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345103","rdfs:label":"Effects of the PLIN1 Variants on Adipose Tissue"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/dcba327c-dc89-4e78-ae7b-84b23db5429e_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5f1f07c7-3389-4896-bcb0-792a6a23fab9","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a365765-320a-4d4a-93e8-5529a251dc8f","type":"Finding","dc:description":"Results in 3T3L1 transfected cells resemble those obtained in patient biopsy findings, namely reduced expression levels of the 439fs mutant as compared to the WT protein.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25114292","rdfs:label":"Expression in stably transfected 3T3L1 preadipocytes","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5af3633d-3ce4-4bb1-aa42-3af1144953ce","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e886619-2494-4ee9-919c-24099e966b7b","type":"Finding","dc:description":"This observation is compatible with data from Gandrota et al (PMID: 21345103) showing that adipocyte size of patients carrying mutations predicting elongated perilipin 1 protein  is significantly reduced as compared with that observed in controls.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25114292","rdfs:label":"Lipid droplets morphology in stably transfected 3T3-L1 cells","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d341dbac-4016-4a01-8a43-926a2a00087d","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bc7491b6-f59b-457c-bb2c-6634bd6e4d69","type":"Finding","dc:description":"Peri 1-/- mice had a greater lean body mass and an increased metabolic rate, with total oxygen consumption being 16% greater than wild-type mice at thermoneutrality. The increased oxygen consumption in perilipin null mice reflects a higher energy expenditure contributing to their lean phenotype. This, however, is coupled with the development of insulin resistance, a metabolic characteristic frequently observed in human lipodystrophy.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11371650","rdfs:label":"Oxygen consumption","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/72d66852-5d1e-407d-82f9-a0210b9e40cb","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23f0fc75-f088-45f2-a2c9-7e3a6d83d37f","type":"Finding","dc:description":"Perilipin null (peri-/-) mice, despite consuming the same amount of food as wild-type (peri+/+) mice, exhibited a significant reduction in adipose tissue mass, approximately 30% of that found in wild-type animals. In humans, PLIN1 framshift mutations leading to an elogated form of perilipin 1 are associated with severe lipodystrophy.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11371650","rdfs:label":"Adipose tissue mass evaluation in Plin1-/- mouse phenotype","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":11663,"specifiedBy":"GeneValidityCriteria11","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/5ZY3V6r9PGc","type":"GeneValidityProposition","disease":"obo:MONDO_0013478","gene":"hgnc:9076","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_dcba327c-dc89-4e78-ae7b-84b23db5429e-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}